Do we still need chemotherapy for AIDS-associated Kaposi's sarcoma?

Expert Rev Anticancer Ther. 2013 Feb;13(2):203-9. doi: 10.1586/era.12.179.

Abstract

The widespread introduction of effective combination antiretroviral therapy (cART) has had a major influence on the epidemiology and natural history of AIDS-associated Kaposi's sarcoma (AIDS-KS). cART has reduced the incidence of AIDS-KS, and it has been shown to be an effective treatment for early-stage KS. So with the widespread availability of cART, is systemic chemotherapy still required for AIDS-KS? Two indications appear to remain: advanced-stage AIDS-KS and patients who have progressive KS despite effective cART including immune reconstitution inflammatory syndrome KS.

Publication types

  • Review

MeSH terms

  • AIDS-Related Opportunistic Infections / drug therapy*
  • AIDS-Related Opportunistic Infections / mortality
  • Anti-Retroviral Agents / therapeutic use*
  • Humans
  • Immune Reconstitution Inflammatory Syndrome / drug therapy
  • Sarcoma, Kaposi / drug therapy*
  • Sarcoma, Kaposi / mortality
  • Treatment Outcome

Substances

  • Anti-Retroviral Agents

Supplementary concepts

  • AIDS-related Kaposi sarcoma